How Artificial Intelligence is Transforming Clinical Trials: The Case of AstraZeneca 

How Artificial Intelligence is Transforming Clinical Trials The Case of AstraZeneca

Table of Contents

In a world where it seems everyone is talking about artificial intelligence, and its numerous benefits, we cannot ignore the fact that artificial intelligence is transforming industries and sectors all over the world and one of them is the pharmaceutical area.

Essentially, AI is a robust tool helping to overcome large problems associated with clinical trials, which eventually helps to speed up the development of new treatments.

AI in Clinical Trials Metrics and Facts:

  1. AI-enabled workflows can save up to 40% of the time required to bring a new molecule for a complex target to the preclinical candidate (PCC) stage.
  2. Cost savings for such a molecule can reach 30% by the preclinical candidate stage.
  3. The global market for AI-powered solutions in clinical trials is expected to exceed $7 billion by 2030, a significant increase from $1.3 billion in 2021.
  4. The generative AI market for clinical trials worldwide is projected to surpass $1 billion by 2032.

How AI Transforms Clinical Trials

Here are some of the ways that AI transforms clinical trials:

 

  • Patient Matching: AI algorithms look at a patient’s data to find ideal matches for a specific trial. As a result of the reduced trial time and streamlined research, they are searching for them more quickly. Several trials are suitable for leading.
  • Predictive analytics: AI analyses past data to predict potential risks and find patients most likely to have a beneficial response to treatment. As part of the more beneficial process, trials are modified.
  • Virtual trial assistants: Leave: chat teams, AI-driven chatbots, can respond to patient questions, inquiries and questions, and more. appoint, develop, and rehire; recruit.
  • Drug development: Design, and phase AI learn vast chemical databases to identify successful drug suppliers, so you won’t have to use the entire library in the manufacturing phase.

How AstraZeneca uses AI in Clinical Trials?

AstraZeneca, a leading pharmaceutical company, has actively embraced AI in clinical trials.

 

AstraZeneca uses AI algorithms to analyze vast datasets and identify potential drug targets. AI assists in predicting disease mechanisms and understanding protein structures, enabling more effective drug design. AI streamlines trial design by predicting trial success based on drug molecules, target diseases, and patient eligibility criteria.

 

Also, AI algorithms help AstraZeneca recruit suitable patients for clinical trials by analyzing patient profiles and medical records. Real-time data analysis ensures efficient trial monitoring and faster decision-making. AI monitors adverse events, identifies safety signals, and ensures compliance with regulatory requirements.

Challenges to Implement AI in Clinical Trials

While AI holds immense promise, significant challenges need to be addressed:

 

  • Data Quality and Bias: AI algorithms are only as good as the data they are trained on. Biased or incomplete data sets can lead to inaccurate or discriminatory outcomes. Ensuring high-quality, diverse data is crucial for responsible AI implementation.
  • Compliance Landscape: Compliance frameworks for AI use in clinical trials are still evolving. Clear guidelines and oversight are necessary to ensure patient safety and ethical conduct of AI-powered research.
  • The Black Box Problem: The complex inner workings of some AI algorithms can be opaque. This lack of transparency can raise concerns about explainability and accountability in clinical trial settings.
  • Technical Expertise: Integrating AI effectively requires expertise in both AI technology and clinical research methodologies. Building a workforce with the necessary skillset is crucial for successful implementation.

Addressing the AI Challenges in Clinical Trials with Integra IT

Despite these challenges, the potential benefits of AI in clinical trials are too significant to ignore. By establishing clear guidelines, fostering data quality, and promoting transparency in AI algorithms.

 

Here’s exciting news! Integra IT is about to launch a new version of TrialPal that incorporates cutting-edge AI features, such as multimedia (images, text, audio, and video) generation per section and data predictions.

 

Stay Updated with Integra IT

 

Subscribe to our LinkedIn newsletter to receive updates on the full implementation of these AI tools on TrialPal.

References:

  1. AstraZeneca. (n.d.). Unlocking the potential of data and AI-driven drug discovery & development. https://www.astrazeneca.com/r-d/data-science-and-ai.html

Share This Post

More To Explore

error: Content is protected !!